Drug Approval | March 06, 2022
USFDA approves expanded use of Bristol Myers Opdivo
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
Novel technology combines ACUVUE daily disposable contact lenses with an established antihistamine in FDA- first in its new category
The guidance also urges companies to act quickly to initiate a recall when public health is at risk and to do so prior to completing an investigation into the cause of the problem
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
ChipCytometry delivers single-cell targeted spatial proteomics for complex whole-tissue analysis of the tumour microenvironment, as well as deep immune profiling for applications in immunology, neuroscience, and infectious disease
Collaboration aims to capture patient-to-patient variability to determine the best treatment for every cancer
OmniActive seeks to improve lives by enhancing nutrition and wellness through science and innovation
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
Subscribe To Our Newsletter & Stay Updated
